GlassScriptPhysician profile
Allison Jo Moosally
NPI 1104847334
$4,766.81
in general payments reported to CMS, 2019-2025
38 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $124 · 2021: $373 · 2022: $1,065 · 2023: $825 · 2024: $927 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.93 | 2019-2025 | |
| Lilly USA, LLC | $353.78 | 2020-2025 | Taltz, Ebglyss |
| Pfizer INC. | $277.54 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $265.58 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Leo Pharma INC. | $230.54 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $216.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $206.92 | 2019-2025 | |
| Incyte Corporation | $170.24 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $153.31 | 2022-2025 | Tremfya, Simponi, Remicade |
| Dermavant Sciences, INC. | $138.67 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $130.10 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $125.17 | 2019-2024 | |
| Revance Therapeutics, INC. | $122.74 | 2024 | Daxxify |
| Ucb, INC. | $104.96 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.38 | 2019-2024 | Arazlo, Cabtreo, Jublia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $92.67 | 2022-2024 | Sotyktu |
| Organon LLC | $72.29 | 2024 | |
| Amgen INC. | $69.64 | 2019-2023 | Otezla |
| Mayne Pharma Commercial LLC | $68.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.17 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $42.81 | 2019 | |
| Allergan, INC. | $36.95 | 2022 | |
| Celgene Corporation | $36.57 | 2019 | |
| Biofrontera INC. | $35.11 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $33.96 | 2019 | |
| Vyne Pharmaceuticals INC. | $31.64 | 2020 | |
| Arcutis Biotherapeutics, INC. | $31.31 | 2023-2024 | Zoryve |
| Aclaris Therapeutics, INC. | $23.55 | 2019 | |
| Epi Health, LLC | $23.38 | 2021 | |
| Lnhc, INC | $22.99 | 2025 | Zelsuvmi |
| Nobelpharma America, LLC | $20.76 | 2023 | |
| Dusa Pharmaceuticals, INC. | $20.26 | 2019 | |
| Organogenesis INC. | $19.63 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $17.54 | 2025 | Hemangeol |
| Conmed Corporation | $16.08 | 2024 | Visiclear |
| Smith+Nephew, INC. | $15.26 | 2019 | |
| Triad Life Sciences INC. | $14.60 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Moosally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.